Orphazyme A/S
Change company Symbol lookup
Select an option...
ORPH Orphazyme A/S
MRDY Mobile Ready Entertainment Corp
MANT ManTech International Corp
LXFR Luxfer Holdings PLC
SYZLF Sylogist Ltd
BSX Boston Scientific Corp
PNGAY Ping An Insurance Group Co of China Ltd
GLOP GasLog Partners LP
AGNC Agnc Investment Corp
TSOEX TIAA-CREF Social Choice International Equity Fund (Retirement)
Go

Health Care : Biotechnology | Small Cap Growth
Based in Denmark
Company profile

Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$4.70
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 163,075 shares is on pace to be much lighter than ORPH's 10-day average volume of 3,218,412 shares.

163,075

Latest Earnings (Q3 ending 09/2020)

Q3
--
Q3 Consensus estimate
-$0.70

Latest Earnings Estimate Range

Highest
estimate
-$0.70
Mean
estimate
-$0.70
Lowest
estimate
-$0.70

Quarterly Consensus Estimates and Ranges

ORPH's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.